Dashboard
1
The company has declared Positive results for the last 18 consecutive quarters
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- NET SALES(Q) Highest at CNY 1,216.02 MM
- OPERATING PROFIT(Q) Highest at CNY 472.2 MM
2
With ROE of 34.50%, it has a fair valuation with a 12.11 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 29,448 Million (Large Cap)
35.00
NA
0.86%
-0.23
30.00%
8.52
Revenue and Profits:
Net Sales:
1,216 Million
(Quarterly Results - Dec 2025)
Net Profit:
372 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.66%
0%
-1.66%
6 Months
-10.07%
0%
-10.07%
1 Year
-9.63%
0%
-9.63%
2 Years
31.65%
0%
31.65%
3 Years
67.12%
0%
67.12%
4 Years
177.22%
0%
177.22%
5 Years
112.61%
0%
112.61%
Xiamen Amoytop Biotech Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
35.99%
EBIT Growth (5y)
54.60%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
1.11
Tax Ratio
10.37%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.89%
ROE (avg)
22.33%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
12.11
EV to EBIT
31.38
EV to EBITDA
28.56
EV to Capital Employed
15.64
EV to Sales
10.47
PEG Ratio
0.78
Dividend Yield
0.76%
ROCE (Latest)
49.85%
ROE (Latest)
34.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,216.00
968.90
25.50%
Operating Profit (PBDIT) excl Other Income
472.20
272.20
73.48%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
0.50
-100.00%
Consolidate Net Profit
371.60
238.20
56.00%
Operating Profit Margin (Excl OI)
388.30%
280.90%
10.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 25.50% vs 15.72% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 56.00% vs -3.09% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,695.60
2,806.30
31.69%
Operating Profit (PBDIT) excl Other Income
1,253.60
1,023.40
22.49%
Interest
0.00
0.60
-100.00%
Exceptional Items
0.00
0.90
-100.00%
Consolidate Net Profit
1,037.70
827.60
25.39%
Operating Profit Margin (Excl OI)
339.20%
331.40%
0.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 31.69% vs 34.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 25.39% vs 49.01% in Dec 2024
About Xiamen Amoytop Biotech Co. Ltd. 
Xiamen Amoytop Biotech Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






